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ABSTRACT- Purpose. Statins are widely prescribed drugs for lowering cholesterol. Some studies have 
suggested that statins can prevent breast cancer recurrence and reduce mortality rate. However they are not 
conclusive. Present systematic review and meta-analysis of published cohort studies was conducted to determine 
the effects of statins intake and risk of breast cancer recurrence and mortality rate. Methods. Online databases 
(PubMed, Embase, Scopus, EBSCO and Cochrane Collaboration) were searched through October 2014. Pooled 
relative risks and 95 % confidence intervals were calculated with random-effects. Results. A total of 8 cohort 
studies (4 for recurrence 2 for mortality and 2 for both) involving 124669 participants with breast cancer were 
eligible. Our results suggest a significant reduction in  recurrence (OR= 0.79. I2= 38%) and death (OR = 0.84, I2 
= 8.58 %) among statin users. Conclusion. Our meta-analysis suggests that breast cancer patients will benefit 
from statin intake, however from these cohorts we are unable to differentiate between various statins in terms of 
effectiveness and duration of use. We highly propose conducting randomized clinical trials. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
__________________________________________________________________________________________ 
 
INTRODUCTION 
 
Breast cancer is one of the most invasive cancers and 
a leading cause of mortality in women (1). Despite 
the discovery of new adjuvant treatments, breast 
cancer recurrence is not an uncommon problem in 
these patients. Therefore, finding new strategies to 
overcome cancer recurrence seem reasonable (2). 
Statins are well-known lipid-lowering drugs which 
can prevent cardiovascular diseases (3). They are 
well-tolerated and serious side effects are rare (4). 
Statins also show some promising effects on 
inhibiting mammary tumor growth and exhibit 
possible anti-carcinogenic properties (5). Previous 
studies in triple negative breast cancer cell lines have 
shown that statins prevent DNA binding of nuclear 
factor kappa beta at the phosphate and tensin 
homolog promoter (6).  Statins also block the 
mevalonate pathway and deplete cholesterol 
precursors such as farnesyl pyrophosphate (FPP) and 
geranyl pyrophosphate (GPP), which decrease the 
ability of cells to perform post-translational protein  
 
prenylation, resulting in blocking the function of 
proteins in breast cancer cell lines (7,8). Despite the 
preclinical results, no prospective randomized 
control trials (RCTs) have evaluated the effects of 
statins on reduction of breast cancer risk.  However, 
several studies have investigated the association 
between statin use and risk of breast cancer. Two 
meta-analyses have been conducted to evaluate the 
combined results of heterogeneous populations. The 
authors in both studies found no association between 
statin use and the risk of breast cancer, however there 
were some limitations in these studies especially 
among high risk populations (9). Subsequently, we 
propose that exposure to statin 1 year before tumor 
detection may influence the cancer phenotype and 
decrease the grade and stage  
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of tumors in comparison with the total number of 
tumors (10). Statins also target histone deacetylase 
(11). Drugs which inhibit histone deacetylation have 
been approved for lymphoma and some other cancer 
treatment except for breast cancer (12). Based on 
these evidences some other studies have 
hypothesized that patients with already diagnosed 
breast cancer may benefit from statin administration. 
However, these studies have yielded mixed results, 
some indicate significant reduction in secondary 
breast cancer recurrence and mortality (2,13,14) 
while others have found non-meaningful effects 
(14,15-17). We aimed to conduct a systematic 
review and meta-analysis of these studies to 
summarize the evidence between statin use and risk 
of secondary breast cancer and mortality. We also 
tried to evaluate whether these associations varied by 
study design, type of statin use and breast cancer site, 
which may help resolve inconsistencies among the 
results from the different studies. 
 
Material and methods 
 
The present study was conducted in accordance with 
the Meta-analysis Of  Observational Studies in 
Epidemiology (MOOSE) guidelines for reviews of 
observational studies (18). 
 
Search strategies  
A literature search of database (PubMed, Embase, 
Scopus, EBSCO and Cochrane Collaboration) was 
conducted using relevant key word: (Statin OR 
HMG-CoA reductase inhibitors OR Atorvastatin OR 
Cerivastatin OR Fluvastatin OR Lovastatin OR 
Pravastatin OR Rosuvastatin OR Simvastatin) AND 
(breast) AND (Cancer OR Neoplasm) AND 
(recurrence OR relapse OR secondary OR mortality 
OR death). Additionally, the relevant reviews and 
retrieved articles were searched manually for more 
eligible studies through October 2014. 
The following information was abstracted from 
each study: study design, country of participants, 
deﬁnition and numbers of cases and control subjects, 
frequency of recurrence cases, and number of 
cancer-specific motility. All studies taken into 
account presented preferably estimated HRs 
corrected for potential confounders.  
 
STATISTICAL ANALYSIS 
 
Heterogeneity was assessed using the Cochran Q and 
I2 statistics. For the Q statistic, a P value<0.10 was 
considered statistically significant for heterogeneity; 
for the I2 statistic, heterogeneity was interpreted as 
moderate (I2: 50%–75%), or high (I2 >75%) (19). 
The overall analysis including all eligible studies 
was performed to assess the association between 
statin use and breast cancer recurrence and mortality 
rate. Pooled HR estimates and corresponding 95% 
CIs were calculated using the inverse variance 
method. In the absence of a statistically signiﬁcant 
heterogeneity (I2: 0%–25%), fixed model was used. 
To test the robustness of association and characterize 
possible sources of statistical heterogeneity, 
sensitivity analysis was carried out by excluding 
studies one-by-one and by analyzing the 
homogeneity and effect size for the remaining 
studies. Publication bias was assessed using Begg 
and Mazumdar adjusted rank correlation test and the 
Egger regression asymmetry test (20, 21). All P-
values were two-tailed. For all tests, a probability 
level of <0.05 was considered statistically 
significant. All calculations and graphs were carried 
out using Comprehensive Meta-Analysis version 2 
(Biostat, Englewood, NJ). 
 
RESULTS 
 
Study selection:   
Figure.1 shows the process of study selection for the 
meta-analysis. Twenty one relevant references were 
initially identified during our search. After screening 
titles and abstracts, 8 were selected for full-text 
review.  
 
Study characteristics 
Table 1 summarizes the characteristics of qualified 
studies in this meta-analysis. The 8 studies, 
involving 124669 participants with breast cancer, 
were published up until October 2014. Among the 
study participants, 25927 were statin users. There 
were 38071 cases of breast cancer recurrences or 
death, determined. 
 
Breast Cancer Recurrence rate and the use of 
statins  
On meta-analysis of all studies assessing the risk of 
recurrence, the use of statins was associated with a 
statistically significant 21% reduction in recurrence 
rate (unadjusted OR= 0.792; 95% CI: 0.735–0.853) 
(Figure.2). There was no considerable heterogeneity 
observed across studies (Cochran's Q-test, P < 0.061; 
I2 = 38%). To assess whether any one study had a 
dominant effect on the meta-analytic HR, each study 
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was excluded and its effect on the main summary 
estimate and Cochran's Q-test P value for 
heterogeneity was evaluated. No study significantly 
affected the summary estimate. There was no 
evidence of significant publication bias, both 
quantitatively (Egger's regression test, P = 0.084) 
and on visual inspection of the funnel plot (Figure 3). 
 
Breast cancer-specific mortality and the use of 
statins 
On meta-analysis of all studies assessing breast 
cancer-specific mortality, the use of statins was 
associated with a statistically significant 16% 
reduction in cancer-specific mortality rate 
(unadjusted OR= 0.849; 95% CI: 0.827–0.870) 
(Figure.4). There was no considerable heterogeneity 
observed across studies (Cochran's Q-test, P =0.360; 
I2=8.58%). To assess whether any one study had a 
dominant effect on the meta-analytic HR, each study 
was excluded and its effect on the main summary 
estimate and Cochran's Q-test P value for 
heterogeneity was evaluated. No study significantly 
affected the summary estimate. There was no 
evidence of significant publication bias, both 
quantitatively (Egger's regression test, P = 0.464) 
and on visual inspection of the funnel plot (Figure 5). 
 
DISCUSSION  
 
Despite some authors’ belief that the use of statins 
may not have any significant protective effects on 
breast cancer recurrence (17), findings from our 
systematic review and meta-–analysis propose 
that statin intake will significantly decrease the 
risk of recurrence (OR= 0.79) and rate of 
mortality (OR=0.84). To the best of our 
knowledge this is the first meta-analysis on statin 
use and breast cancer recurrence and mortality. 
We analyzed 6 and 4 cohort studies (2 for both 
mortality and death) for detection of statins effect 
on recurrence and mortality rate, respectively.  
High doses of fluvastatin as neo-adjuvants 
significantly decreases breast cancer proliferation 
(22),(23). As another possible mechanism, it is 
proposed that simvastatin stimulates production of a 
variant of the p53 transcription factor and reduces 
bone metastases (24). Statins inhibit breast cancer 
cell growth in vitro which may demonstrate the 
biological plausibility to statins’ preventive effect on 
breast cancer progression (25). A pre-surgical 
clinical trial reported antiproliferative effect of 
atorvastatin on invasive breast cancer at 80 mg/day 
dose for two weeks (26).  This effect was shown only 
in tumors expressing HMGCR (3-Hydroxy-3-
Methylglutaryl-CoA Reductase), proposing that 
statins target this enzyme in breast cancer tissue. 
They also decreased estrone sulfate level which is 
another possible mechanism for the anti-cancer 
action (27).  
Mutant p53 up-regulates the mevalonate 
pathway which induces an invasive phenotype. 
Adding  simvastatin to the culture medium reverses 
this phenotype to normal morphology, however the 
malignant phenotype persist when both simvastatin 
and geranylgeranylpyrophosphate (GGPP)  are 
present in the medium (28). 
The initial report of association between post-
diagnosis statin use and risk of breast cancer came 
from a large US cohort. The mean duration of statin 
use was 1.96, and HR of 0.67, 0.8 and 0.38 were 
obtained from less than 100 days, between 100 days 
and two years, and more than 2 years of treatment 
respectively. In this study the patients mainly used 
lipophilic statin (16).  
A second report was obtained from a cohort 
study of Danish breast cancer patients. In this study 
patients were followed up for 6.8 years after 
diagnosis. Overall HR was 0.83, but 0.7 for 
simvastatin alone. The authors concluded that while 
simvastatin had significant effects, hydrophilic 
statins had no effects(13). 
In a cohort of 703 breast cancer patients, it had 
been showed that use of statins for more than 6 
months significantly reduced the risk of cancer 
recurrence. The study associated usage of statins 
with a lower recurrence rate (adjusted HR = 0·48) 
(2). 
Mortality rate was assessed among patients 40 
years and older who had used statin, in a cohort of 
Danish population. Authors evaluated risk with daily 
doses of statins and found HR of 0.83, 0.87 and 0.87 
for 0.01-0.75, 0.75-1.5 and higher than 1.5 daily, 
respectively (15).  
In 2013, one study evaluated the effect of statins 
on recurrence and mortality in primary inflammatory 
breast cancer, a rare form of breast cancer. This study 
also supports the protective role of lipophilic statins 
on inflammatory breast cancer (29).  
Another large study on a prospective cohort of 
3,024 non-metastatic breast cancer was conducted 
recently, which showed non-significant reduction in 
cancer recurrence with HR of 0.83 for stage I and III 
and 0.84 for menopausal women, however the 
authors also found an overall increase in the risk of 
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cancer mortality rate. The authors in this study did 
not support the role of statins in the reduction of 
breast cancer recurrence and mortality rate (17).  
In a U.S. prospective cohort study of 4,216 
women with breast cancer, use of lipophilic statins 
decreased the rate of breast cancer recurrence (HR = 
0·76), however hydrophilic statins had no effect (HR 
= 1·01) (14).  
The most recent cohort from Finland (31236 
participants) showed decreased risk of mortality in 
patients taking statin post and pre diagnostic 
(HR=0.46 and HR= 0.54).  Authors believed that 
decrease due to post-diagnostic statin use was likely 
affected by healthy adherer bias and was not clearly 
dose-dependent (30).  
Although these results propose that statins, 
especially simvastatin, can reduce cancer recurrence, 
it should be mentioned that perhaps other patient 
characteristics and not lipid-lowering medication is 
responsible for the underlying mechanism for the 
observed results. Also increased levels of cholesterol 
might reduce the risk of metastases (31). In a recent 
meta-analysis, the authors have shown the beneficial 
effects of statin in prevention of cancer death 
especially in colon cancer patients. The previous 
study did not calculate the effect of statin use on 
breast cancer recurrence risk (32). Well-designed 
studies considering statins consumption, as well as 
cholesterol levels, are required in order to clarify the 
specific role of statins in the chemoprevention of 
breast cancer recurrence.  
In conclusion, our analysis of the available data 
suggests that statin use results in 21% reduction in 
breast cancer recurrence and 16% reduction in 
mortality rate. This provides a justification for 
launching further randomized clinical trials.   
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Figure 1. Flowchart representing the selection process ASCO American society of clinical oncology 
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 Figure 2. Overall meta-analysis of statin use and Breast Cancer Recurrence (a1: Statin usage <1 year , a2:Statin usage 1-2.9 
years , a3: Statin usage more than 3 years; b1:Patients with stage I-III of breast cancer, b2:Patients with stage I-III of breast 
cancer (only postmenopausal); c1:Any type of statin user, c2:lipophilic statin user, c3:Weakly lipophilic and hydrophilic statin 
users; d1:Users of any statin, d2: User of only hydrophilic, d3: User of only lipophilic, d4:User of only simvastatin; e1:Any 
statin usage >100 days supply, e2: Any statin use for 101 days – ≤2 years supply, e3:Any statin use >2 years supply). 
 
 
 
  
Figure 3. Funnel plot for publication bias in the studies investigating risk for Breast cancer recurrence associated with use of 
statins. 
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Figure 4. Overall meta-analysis of statin use and Breast Cancer mortality(a1: pre-diagnostic statin use (Intensity of statin 
use(195 DDDs/year or less)), a2: pre-diagnostic statin use (Intensity of statin use (Over 196 DDDs/years)), a3: post-diagnostic 
statin use (Intensity of statin use(14–183 DDDs/year)), a4: post-diagnostic statin use (Intensity of statin use (184–300 
DDDs/year)), a5: post-diagnostic statin use (Intensity of statin use(301 DDDs/year or more)); b1: Patients with stage I–IV, 
a2: Patients with stage I–III, b3: stage I–III (only postmenopausal); c1: lipophilic statin user, c2: Weakly lipophilic and 
hydrophilic statin users, d1: For 0.01 to 0.75 defined daily statin dose per day, d2: For0.76 to 1.50 defined daily statin dose 
per day, d3:For higher than 1.50 defined daily statin dose per day). 
 
 
 Figure 5. Funnel plot for publication bias in the studies investigating risk for Breast cancer-specific mortality associated with 
use of statins.  
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Table 1.  Cohort Studies of Statins Use and risk of breast cancer recurrence and mortality rate in the systematic reviews and meta-analyses. 
Country 
(Reference) 
 
Follow up 
duration 
 
Number of patients 
 HR (95% CI) for recurrence and/or 
[mortality] (users vs non-users of statin) Controlled variables 
Total Statin users 
 
Recurrence and/or 
mortality 
Denmark 
(13) 1996-2003 18769 3282 
 
 
 
 
3419 
Users of any statin, 0.83 (0.70, 0.98) 
User of only hydrophilic 1.2 (0.79, 1.7) 
User of only lipophilic 0.73 (0.60, 0.89) 
User of only simvastatin 0.70 (0.57,  0.86) 
Age, menopausal status at diagnosis, 
histological grade, ER status and receipt 
of adjuvant ET,  type of primary surgery 
received, pre-diagnosis exposure to 
combination hormone replacement 
therapy, and co-prescriptions of special 
drugs 
USA (2) 
 
1999 - 
2005 703 156 
 
 
149 0.40 (0.24, 0.67) 
Age, race, menopausal status at 
diagnosis, family history of disease, 
smoking history, diabetes, hormonal 
receptor status, and hormonal therapy 
status. 
USA (14) 1990-2008 4226 1210 
 
 
 
 
 
371 
Statin usage <1 year,  0.79 (0.47, 1.33) 
Statin usage 1-2.9 years,  0.75 (0.46, 1.22) 
Statin usage more than 3 years,  0.91 (0.78, 
1.05) 
Age, diagnosis year, 
AJCC stage, hormone receptor status, 
primary treatment for initial breast 
cancer, 
endocrine therapy for the incident breast 
cancer status, body mass index at 
diagnosis, 
smoking status, 
menopausal status at diagnosis, Charlson 
co-morbidity score, 
diabetes  status, prescription non-
steroidal anti-inﬂammatories 
USA (16) 1997 -2000 1811 367 
 
 
 
344 
Any statin usage >100 days supply, 
 0.67 (0.39, 1.14) 
Any statin use for 101 days – ≤2 years supply, 
0.80 (0.45, 1.43) 
Any statin use >2 years supply, 0.38 (0.12, 
1.19) 
Age, race, body mass index, stage of 
breast cancer, and tamoxifen treatment, 
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Germany 
(17) 2001 -2005 6213 592 
 
 
 
 
 
 
387 
Patients with stage I-III of breast cancer,  
0.83 (0.53. 1.26) 
Patients with stage I-III of breast cancer (only 
postmenopausal), 0.84 (0.56, 1.25) 
/ 
Patients with stage I–IV, 1.04 (0.67, 1.61) 
Patients with stage I–III: 0.89 (0.53, 1.51) 
stage I–III (only postmenopausal), 0.93 (0.54, 
1.60) 
Age, the traditional prognostic factors tumor 
size, nodal status, and 
smoking. 
 
Mortality analyses are additionally adjusted 
for cardiovascular disease, diabetes mellitus, 
and body-mass index. 
USA (26) 1995-2011 723 73 
There was no 
suitable 
information on 
the recurrence 
data / 338 
Any type of statin user: 0.63 (0.42, 0.95) 
lipophilic statin user, 0.76 (0.41, 1.41),  
 [1.18 (0.54, 2.56)]  
Weakly lipophilic and hydrophilic statin users, 
0.49 (0.28, 0.85), [0.85 (0.46, 1.57)]  
 
 
Radiation therapy, hormonal receptor status, 
lymphatic/vascular invasion for PFS and 
lymphatic/vascular invasion, nuclear grade 
and surgery 
Denmark 
(15) 1995 - 2009 60988 15247 
Studying on the 
recurrence event 
was not the aim of 
this study / 29577 
For 0.01 to 0.75 defined daily statin dose per 
day,  
0.83 (0.80, 0.86) 
For 0.76 to 1.50 defined daily statin dose per 
day,  
0.87 (0.83, 0.91) 
For higher than 1.50 defined daily statin dose 
per day), 0.87 (0.82, 0.92) 
Age, cancer 
Stage, spread to the lymphatic system, 
distant metastasis,  status with regard to 
chemotherapy, radiotherapy, diagnosis of 
cardiovascular disease before cancer, and 
diagnosis of diabetes mellitus before cancer; 
year of birth, sex,  race, ethnic descent, 
education; and size of residential area. 
Finland 
(26) 1995-2003 31236 4151 
Studying on the 
recurrence event 
was not the aim of 
this study / 3486 
Statin intensity*, 14–183: 0.79 (0.51–1.22) 
Statin intensity*, 84–300: 0.42 (0.21–0.84) 
Statin intensity*, 301or more): 0.47 (0.23–
0.94) 
Statin intensity*, 195 or less: 0.82 (0.57–1.17) 
Statin intensity*, 196 or more: 0.63 (0.38–
1.03) 
Age, tumor stage and morphology, and 
treatment selection 
 Measured as post-diagnostic statin density of HMG-CoA reductase.  
 
